Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bannink

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Amino Acids|April 20, 2006
Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patientsD Fekkes, M Bannink, W H J Kruit, et al.
Psycho-Oncology|February 4, 2009
The Distress Thermometer assessed in women at risk of developing hereditary breast cancerS van Dooren, H J Duivenvoorden, J Passchier, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2011
Higher doses of opioids in patients who need palliative sedation prior to death: cause or consequence?A W Oosten, W H Oldenmenger, C van Zuylen, et al.
Digestive Diseases and Sciences|April 1, 1996
Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findingsJ J Kolkman, T H Falke, J C Roos, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 13, 2008
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinomaA R Van Gool, R Verkerk, D Fekkes, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 7, 2004
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patientsA R Van Gool, H H Van Ojik, W H J Kruit, et al.
Plos One|July 5, 2013
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma modelsCecile M Krejsa, Rick D Holly, Mark Heipel, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Amino Acids|April 20, 2006
Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patientsD Fekkes, M Bannink, W H J Kruit, et al.
Psycho-Oncology|February 4, 2009
The Distress Thermometer assessed in women at risk of developing hereditary breast cancerS van Dooren, H J Duivenvoorden, J Passchier, et al.
European Journal of Cancer (Oxford, England : 1990)|July 30, 2011
Higher doses of opioids in patients who need palliative sedation prior to death: cause or consequence?A W Oosten, W H Oldenmenger, C van Zuylen, et al.
Digestive Diseases and Sciences|April 1, 1996
Computed tomography and granulocyte scintigraphy in active inflammatory bowel disease. Comparison with endoscopy and operative findingsJ J Kolkman, T H Falke, J C Roos, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|June 13, 2008
Plasma activity of prolyl endopeptidase in relation to psychopathology during immunotherapy with IFN-alpha in patients with renal cell carcinomaA R Van Gool, R Verkerk, D Fekkes, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|August 7, 2004
Serum activity of prolyl endopeptidase, but not of dipeptidyl peptidase IV, is decreased by immunotherapy with IFN-alpha in high-risk melanoma patientsA R Van Gool, H H Van Ojik, W H J Kruit, et al.
Plos One|July 5, 2013
Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma modelsCecile M Krejsa, Rick D Holly, Mark Heipel, et al.
Pageof 2